NEW YORK--Warner-Lambert Co.'s Parke-Davis division, which markets lipid-regulating gemfibrozil as Lopid, got a boost recently from the findings of a new study on coronary heart disease (CHD) which show that gemfibrozil reduces CHD risk. The information was reported by the American Lipid ...